Table 2 The details of all included studies
Reference | Year | Sample size case/controls | Ethnicity | Chemotherapy agent | Source of data | Genotyping | Cancer site |
|---|---|---|---|---|---|---|---|
Magrangeas | 2016 | 155/314 | European | Bortezomib | RCT | SNP 6.0 Affymetrix arrays | Multiple myeloma |
García-Sanz | 2016 | 33/139 | NA | Bortezomib and/or thalidomide | RCT | Axiom Exome Genotyping array (Affymetrix) | Multiple myeloma |
Hertz | 2016 | 50/566 | Caucasian | Docetaxel | RCT | HumanHap610-Quad Genotyping BeadChip (Illumina) | Prostate cancer |
Komatsu | 2015 | 24/121 | Asian | Paclitaxel | Cohort study | Illumina Omni-Express BeadChip | Cancer (NS) |
Schneider | 2015 | 576/781 | European | Paclitaxel | RCT | HumanOmni1-Quad array (Illumina) | Breast cancer |
Diouf | 2015 | 86/235 | Mixed population | Vincristine | RCT | Affymetrix GeneChip Human Mapping 500 K array 532,552 SNPs) or the SNP 6.0 array (906,600 SNPs) (Affymetrix) | Acute lymphoblastic leukemia (ALL) |
Leandro-García | 2013 | 144 Cox regression | European | Paclitaxel | Cohort study | Infinium BeadChip Human 660WQuad assay (Illumina) | Cancer (NS) |
Baldwin | 2012 | 855 cox regression | European | Paclitaxel | RCT | HumanHap610-Quad Genotyping BeadChip (Illumina) | Breast cancer |
Won | 2011 | 39/57 | Asian | Oxaliplatin | Cohort study | Affymetrix Genome-Wide Human SNP Array 6.0 | Colon cancer |